Routine use of systemic glucocorticoids for patients with COVID-19 cannot be recommended

The investigators found in a review article of 1 RCT and 22 cohort studies, with a total of 13,815 patients, that glucocorticoid therapy may increase the risk of death in patients with coronavirus infections who have mild symptoms and there is no association between glucocorticoids and mortality in patients with severe symptoms. In the context of clinical trials, low dose systemic glucocorticoid therapy for a short duration may be acceptable. Based on these findings, routine use of systemic glucocorticoids for patients with COVID-19 cannot be recommended.

Read more right here:
Routine use of systemic glucocorticoids for patients with COVID-19 cannot be recommended